Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?

Cytologic and molecular characterizations of CTC detected in patients with metastatic colorectal carcinomas.

(2017) Julien Coget et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of serum proteome in patients with metastatic colorectal cancer responsive and nonresponsive to bevacizumab using 2 d-DIGE.

(2017) Petra Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.

(2017) Terence Duane Rhodes et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.

(2017) Satoshi Matsusaka et al.   JOURNAL OF CLINICAL ONCOLOGY

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation

(2012) S.J. Park et al.   LUNG CANCER

Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study

(2011) Kazuhiro Asami et al.   Clinical Lung Cancer

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Qing Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2011) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor

(2011) Britta Weber et al.   Journal of Thoracic Oncology

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

(2011) Sumitra Thongprasert et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

(2011) Seung Tae Kim et al.   LUNG CANCER

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis

(2010) Hironori Uruga et al.   INTERNAL MEDICINE

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer

(2010) David R. Gandara et al.   Journal of Thoracic Oncology

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

(2010) A. F. Eichler et al.   NEURO-ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations

(2009) S. Morita et al.   CLINICAL CANCER RESEARCH

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2009) Tony S.K. Mok et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

(2009) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

(2009) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?

(2009) Kyoung Ha Kim et al.   LUNG CANCER

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

(2008) K Tamura et al.   BRITISH JOURNAL OF CANCER

Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first

(2008) Dae Ho Lee et al.   CANCER

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

(2008) M.-J. Ahn et al.   CLINICAL CANCER RESEARCH

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

(2008) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

(2008) Kenji Sugio et al.   LUNG CANCER